BRISTOL-MYERS SQUIBB COMPANY Current Federal Tax Expense (Benefit)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Current Federal Tax Expense (Benefit) of $1.70 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY current federal tax expense (benefit) for fiscal 2025 was $1.70B, a 32.84% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY current federal tax expense (benefit) for fiscal 2024 was $1.28B, a 53.41% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY current federal tax expense (benefit) for fiscal 2023 was $2.75B, a 9.02% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY current federal tax expense (benefit) for fiscal 2022 was $3.02B, a 60.56% increase from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.70B 10-K · filed 2026-02-11 | |
| 2024-12-31 | $1.28B 10-K · filed 2026-02-11 | |
| 2023-12-31 | $2.75B 10-K · filed 2026-02-11 | |
| 2022-12-31 | $3.02B 10-K · filed 2025-02-12 | |
| 2021-12-31 | $1.88B 10-K · filed 2024-02-13 | |
| 2020-12-31 | $1.25B 10-K · filed 2023-02-14 | |
| 2019-12-31 | $1.00B 10-K · filed 2022-02-09 | |
| 2018-12-31 | $566.00M 10-K · filed 2021-02-10 | $485.00M 10-K · filed 2019-02-25 |
| 2017-12-31 | $3.30B 10-K · filed 2020-02-24 | $2.78B 10-K · filed 2018-02-13 |
| 2016-12-31 | $1.14B 10-K · filed 2019-02-25 | |
| 2015-12-31 | $337.00M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $334.00M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $375.00M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $627.00M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $864.00M 10-K · filed 2014-02-14 | |
| 2010-12-31 | $797.00M 10-K · filed 2013-02-15 | |
| 2009-12-31 | $410.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |